 SHELTON, CT ACCESSWIRE July 8, 2020 NanoViricides, Inc. NYSE American:NNVC the Company a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that excellent safety and tolerability of the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases was observed in an animal model. The nanoviricides drug candidates tested in this safetytolerability study have previously shown strong effectiveness against lung infection by a SARS-CoV-2 like coronavirus, namely, hCoV-NL63, in an animal study as previously reported by the Company. Three different drug candidates at three different dosage levels low, medium, and high and vehicle control were administered to separate groups of mice intravenously in the Safety-Tolerability study reported here. 